Perrigo Long Term Debt 2012-2025 | PRGO
Perrigo long term debt from 2012 to 2025. Long term debt can be defined as the sum of all long term debt fields.
|
Perrigo Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $3,582 |
| 2023 | $3,633 |
| 2022 | $4,070 |
| 2021 | $2,917 |
| 2020 | $3,528 |
| 2019 | $3,366 |
| 2018 | $3,052 |
| 2017 | $3,271 |
| 2016 | $5,225 |
| 2015 | $4,972 |
| 2015 | $5,247 |
| 2014 | $3,063 |
| 2013 | $1,928 |
| 2012 | $1,329 |
| 2011 | $875 |
|
Perrigo Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2025-09-30 | $3,608 |
| 2025-06-30 | $3,616 |
| 2025-03-31 | $3,591 |
| 2024-12-31 | $3,582 |
| 2024-09-30 | $4,313 |
| 2024-06-30 | $3,617 |
| 2024-03-31 | $3,625 |
| 2023-12-31 | $3,633 |
| 2023-09-30 | $4,049 |
| 2023-06-30 | $4,056 |
| 2023-03-31 | $4,063 |
| 2022-12-31 | $4,070 |
| 2022-09-30 | $4,078 |
| 2022-06-30 | $4,086 |
| 2022-03-31 | $3,511 |
| 2021-12-31 | $2,917 |
| 2021-09-30 | $2,921 |
| 2021-06-30 | $2,926 |
| 2021-03-31 | $3,525 |
| 2020-12-31 | $3,528 |
| 2020-09-30 | $3,544 |
| 2020-06-30 | $3,536 |
| 2020-03-31 | $3,183 |
| 2019-12-31 | $3,366 |
| 2019-09-30 | $3,362 |
| 2019-06-30 | $3,084 |
| 2019-03-31 | $2,750 |
| 2018-12-31 | $3,052 |
| 2018-09-30 | $3,071 |
| 2018-06-30 | $3,085 |
| 2018-03-31 | $3,281 |
| 2017-12-31 | $3,271 |
| 2017-09-30 | $3,276 |
| 2017-06-30 | $3,268 |
| 2017-03-31 | $4,619 |
| 2016-12-31 | $5,225 |
| 2016-09-30 | $5,638 |
| 2016-06-30 | $5,653 |
| 2016-03-31 | $5,903 |
| 2015-12-31 | $4,972 |
| 2015-09-30 | $5,230 |
| 2015-06-30 | $5,247 |
| 2015-03-31 | $4,368 |
| 2014-12-31 | $4,439 |
| 2014-09-30 | $3,051 |
| 2014-06-30 | $3,091 |
| 2014-03-31 | $3,126 |
| 2013-12-31 | $3,159 |
| 2013-09-30 | $1,936 |
| 2013-06-30 | $1,928 |
| 2013-03-31 | $1,332 |
| 2012-12-31 | $1,330 |
| 2012-09-30 | $1,330 |
| 2012-06-30 | $1,329 |
| 2012-03-31 | $1,455 |
| 2011-12-31 | $1,453 |
| 2011-09-30 | $1,156 |
| 2011-06-30 | $875 |
| 2011-03-31 | $875 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $2.015B | $4.373B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||